ABSTRACT
Over the last decade, improvements in surgical techniques, lung preservation, immunosuppression,
and management of ischemia-reperfusion injury and infections have contributed to increase
the 1 year patient survival after lung transplantation to 70 to 80%. However, the
incidence of acute rejection remains higher than after other types of solid organ
transplantation, and long-term survival is threatened by bronchiolitis obliterans,
which is thought to be a form of chronic allograft rejection. This article reviews
major aspects of clinical presentation, risk factors, diagnosis, and management of
acute and chronic rejection after lung transplantation.
KEYWORDS
Lung transplantation - acute rejection - immunosuppression - bronchiolitis obliterans
REFERENCES
- 1
Quantz M A, Bennett L E, Meyer D M, Novick R J.
Does human leukocyte antigen matching influence the outcome of lung transplantation?
An analysis of 3,549 lung transplantations.
J Heart Lung Transplant.
2000;
19
473-479
- 2
Kumar D, Erdman D, Keshavjee S et al..
Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans
after lung transplant.
Am J Transplant.
2005;
5
2031-2036
- 3
Vilchez R A, Dauber J, McCurry K, Iacono A, Kusne S.
Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical
syndrome with implications on allograft function.
Am J Transplant.
2003;
3
116-120
- 4
Heeger P S.
T-cell allorecognition and transplant rejection: a summary and update.
Am J Transplant.
2003;
3
525-533
- 5
DeVito Dabbs A, Hoffman L A, Iacono A T et al..
Pattern and predictors of early rejection after lung transplantation.
Am J Crit Care.
2003;
12
497-507
- 6
Palmer S M, Baz M A, Sanders L et al..
Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus
azathioprine in the prevention of acute lung allograft rejection.
Transplantation.
2001;
71
1772-1776
- 7
McNeil K, Glanville A R, Wahlers T et al..
Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis
obliterans syndrome in de novo lung transplant recipients.
Transplantation.
2006;
81
998-1003
- 8
Trulock E P, Edwards L B, Taylor D O, Boucek M M, Keck B M, Hertz M I.
Registry of the International Society for Heart and Lung Transplantation: twenty-second
official adult lung and heart-lung transplant report-2005.
J Heart Lung Transplant.
2005;
24
945-982
- 9
Schulman L L, Weinberg A D, McGregor C, Galantowicz M E, Suciu-Foca N M, Itescu S.
Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after
lung transplantation.
Am J Respir Crit Care Med.
1998;
157
1833-1837
- 10
Keogh A, Kaan A, Doran T, Macdonald P, Bryant D, Spratt P.
HLA mismatching and outcome in heart, heart-lung and single lung transplantation.
J Heart Lung Transplant.
1995;
14
444-451
- 11
Reinsmoen N L, Nelson K, Zeevi A.
Anti-HLA antibody analysis and crossmatching in heart and lung transplantation.
Transpl Immunol.
2004;
13
63-71
- 12
Girnita A L, McCurry K R, Iacono A T et al..
HLA-specific antibodies are associated with high-grade and persistent-recurrent lung
allograft acute rejection.
J Heart Lung Transplant.
2004;
23
1135-1141
- 13
Girnita A L, Duquesnoy R, Yousem S A et al..
HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic
lung allograft dysfunction.
Am J Transplant.
2005;
5
131-138
- 14
Zeier M, Doehler B, Opelz G, Ritz E.
The effect of donor gender on graft survival.
J Am Soc Nephrol.
2002;
13
2570-2576
- 15
Sato M, Gutierrez C, Kaneda H, Liu M, Waddell T K, Keshavjee S.
The effect of gender combinations on outcome in human lung transplantation: the International
Society of Heart and Lung Transplantation Registry experience.
J Heart Lung Transplant.
2006;
25
634-637
- 16
Roberts D H, Wain J C, Chang Y, Ginns L C.
Donor-recipient gender mismatch in lung transplantation: impact on obliterative bronchiolitis
and survival.
J Heart Lung Transplant.
2004;
23
1252-1259
- 17
Gerna G, Vitulo P, Rovida F et al..
Impact of human metapneumovirus and human cytomegalovirus versus other respiratory
viruses on the lower respiratory tract infections of lung transplant recipients.
J Med Virol.
2006;
78
408-416
- 18
Hartwig M G, Appel J Z, Davis R D.
Antireflux surgery in the setting of lung transplantation: strategies for treating
gastroesophageal reflux disease in a high-risk population.
Thorac Surg Clin.
2005;
15
417-427
- 19
McDonald J W, Keller C A, Ramos R R, Brunt E M.
Mixed (neutrophil-rich) interstitial pneumonitis in biopsy specimens of lung allografts:
a clinicopathologic evaluation.
Chest.
1998;
113
117-123
- 20
Zheng H X, Burckart G J, McCurry K et al..
Interleukin-10 production genotype protects against acute persistent rejection after
lung transplantation.
J Heart Lung Transplant.
2004;
23
541-546
- 21
Zheng H X, Zeevi A, McCurry K et al..
The impact of pharmacogenomic factors on acute persistent rejection in adult lung
transplant patients.
Transpl Immunol.
2005;
14
37-42
- 22
Yousem S A, Berry G J, Cagle P T et al..
Revision of the 1990 working formulation for the classification of pulmonary allograft
rejection: Lung Rejection Study Group.
J Heart Lung Transplant.
1996;
15
1-15
- 23
Takemoto S K, Zeevi A, Feng S et al..
National Conference to assess antibody-mediated rejection in solid organ transplantation.
Am J Transplant.
2004;
4
1033-1041
- 24
Bittner H B, Dunitz J, Hertz M, Bolman III M R, Park S J.
Hyperacute rejection in single lung transplantation-case report of successful management
by means of plasmapheresis and antithymocyte globulin treatment.
Transplantation.
2001;
71
649-651
- 25
Saint Martin G A, Reddy V B, Garrity E R, Simpson K, Rob Husain A N.
Humoral (antibody-mediated) rejection in lung transplantation.
J Heart Lung Transplant.
1996;
15
1217-1222
- 26
Badesch D B, Zamora M, Fullerton D et al..
Pulmonary capillaritis: a possible histologic form of acute rejection.
J Heart Lung Transplant.
1998;
17
415-422
- 27
Magro C M, Deng A, Pope-Harman A et al..
Humorally mediated posttransplantation septal capillary injury syndrome as a common
form of pulmonary graft rejection: a hypothesis.
Transplantation.
2002;
74
1273-1280
- 28
Astor T L, Well D, Cool C, Teitelbaum I, Schwarz M I, Zamora M R.
Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft
function.
J Heart Lung Transplant.
2005;
24
2091-2097
- 29
Haccuria A, Knoop C, Magro C et al..
Primary graft dysfunction after lung transplantation: acute humoral rejection may
play a causative role [abstract].
J Heart Lung Transplant.
2006;
25
S185
- 30
Kukafka D S, O'Brien G M, Furukawa S, Criner G J.
Surveillance bronchoscopy in lung transplant recipients.
Chest.
1997;
111
377-381
- 31
Hopkins P M, Aboyoun C L, Chhajed P N et al..
Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis.
Am J Respir Crit Care Med.
2004;
170
1022-1026
- 32
Khalifah A P, Hachem R R, Chakinala M M et al..
Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans
syndrome.
Am J Transplant.
2005;
5
2022-2030
- 33
Hachem R R, Khalifah A P, Chakinala M M et al..
The significance of a single episode of minimal acute rejection after lung transplantation.
Transplantation.
2005;
80
1406-1413
- 34
Muthukumar T, Dadhania D, Ding R et al..
Messenger RNA for FOXP3 in the urine of renal-allograft recipients.
N Engl J Med.
2005;
353
2342-2351
- 35
De Vito Dabbs A, Hoffman L A, Iacono A T, Zullo T G, McCurry K R, Dauber J H.
Are symptom reports useful for differentiating between acute rejection and pulmonary
infection after lung transplantation?.
Heart Lung.
2004;
33
372-380
- 36
Kundu S, Herman S J, Larhs A et al..
Correlation of chest radiographic findings with biopsy-proven acute lung rejection.
J Thorac Imaging.
1999;
14
178-184
- 37
Loubeyre P, Revel D, Delignette A, Loire R, Mornex J F.
High-resolution computed tomographic findings associated with histologically diagnosed
acute lung rejection in heart-lung transplant recipients.
Chest.
1995;
107
132-138
- 38
Gotway M B, Dawn S K, Sellami D et al..
Acute rejection following lung transplantation: limitations in accuracy of thin-section
CT for diagnosis.
Radiology.
2001;
221
207-212
- 39
Morlion B, Knoop C, Paiva M, Estenne M.
Internet-based home monitoring of pulmonary function after lung transplantation.
Am J Respir Crit Care Med.
2002;
165
694-697
- 40
Van Muylem A, Mélot C, Antoine M, Knoop C, Estenne M.
Role of pulmonary function in the detection of allograft dysfunction after heart-lung
transplantation.
Thorax.
1997;
52
643-647
- 41
Slebos D J, Postma D S, Koeter G H, van der Bij W, Boezen M, Kauffman H F.
Bronchoalveolar lavage fluid characteristics in acute and chronic lung transplant
rejection.
J Heart Lung Transplant.
2004;
23
532-540
- 42
Ericson P, Linden A, Riise G C.
BAL levels of interleukin-18 do not change before or during acute rejection in lung
transplant recipients.
Respir Med.
2004;
98
159-163
- 43
Studer S M, Orens J B, Rosas I et al..
Patterns and significance of exhaled-breath biomarkers in lung transplant recipients
with acute allograft rejection.
J Heart Lung Transplant.
2001;
20
1158-1166
- 44
Aharinejad S, Taghavi S, Klepetko W, Abraham D.
Prediction of lung transplant rejection by hepatocyte growth factor.
Lancet.
2004;
363
1503-1508
- 45
Palmer S M, Miralles A P, Lawrence C M, Gaynor J W, Davis F RD.
Rabbit antithymocyte globulin decreases acute rejection after lung transplantation:
results of a randomized, prospective study.
Chest.
1999;
116
127-133
- 46
Brock M V, Borja M C, Ferber L et al..
Induction therapy in lung transplantation: a prospective, controlled clinical trial
comparing OKT3, anti-thymocyte globulin, and daclizumab.
J Heart Lung Transplant.
2001;
20
1282-1290
- 47
Hachem R R, Chakinala M M, Yusen R D et al..
A comparison of basiliximab and anti-thymocyte globulin as induction agents after
lung transplantation.
J Heart Lung Transplant.
2005;
24
1320-1326
- 48
Burton C M, Andersen C B, Jensen A S et al..
The incidence of acute cellular rejection after lung transplantation: a comparative
study of anti-thymocyte globulin and daclizumab.
J Heart Lung Transplant.
2006;
25
638-647
- 49
Keenan R J, Konishi H, Kawai A et al..
Clinical trial of tacrolimus versus cyclosporine in lung transplantation.
Ann Thorac Surg.
1995;
60
580-585
- 50
Reichenspurner H, Kur F, Treede H et al..
Optimization of the immunosuppressive protocol after lung transplantation.
Transplantation.
1999;
68
67-71
- 51
Treede H, Klepetko W, Reichenspurner H et al..
Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized
two-center trial comparing two different immunosuppressive protocols.
J Heart Lung Transplant.
2001;
20
511-517
- 52
Zuckermann A, Reichenspurner H, Birsan T et al..
Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids
as primary immunosuppression after lung transplantation: one-year results of a two-center
prospective randomized trial.
J Thorac Cardiovasc Surg.
2003;
125
891-900
- 53
Sarahrudi K, Estenne M, Corris P et al..
International experience with conversion from cyclosporine to tacrolimus for acute
and chronic lung allograft rejection.
J Thorac Cardiovasc Surg.
2004;
127
1126-1132
- 54
Iacono A T, Johnson B A, Grgurich W F et al..
A randomized trial of inhaled cyclosporine in lung-transplant recipients.
N Engl J Med.
2006;
354
141-150
- 55
Aboyoun C L, Tamm M, Chhajed P N et al..
Diagnostic value of follow-up transbronchial lung biopsy after lung rejection.
Am J Respir Crit Care Med.
2001;
164
460-463
- 56 Orens J B, Studer S, Levy R D.
Acute allograft rejection. In: Lynch III JP, Ross DJ Lung and Heart-Lung Transplantation. New York; Taylor
and Francis Group 2006: 661-681
- 57
Jordan S C, Vo A A, Tyan D, Nast C C, Toyoda M.
Current approaches to the treatment of antibody-mediated rejection.
Pediatr Transplant.
2005;
9
408-405
- 58
Burke C M, Theodore J, Dawkins K D et al..
Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung
transplantation.
Chest.
1984;
86
824-829
- 59
Estenne M, Maurer J R, Boehler A et al..
Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria.
J Heart Lung Transplant.
2002;
21
297-310
- 60
Jackson C H, Sharples L D, McNeil K, Stewart S, Wallwork J.
Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different
entities?.
J Heart Lung Transplant.
2002;
21
658-666
- 61
Heng D, Sharples L D, McNeil K, Stewart S, Wreghitt T, Wallwork J.
Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk
factors.
J Heart Lung Transplant.
1998;
17
1255-1263
- 62
Bando K, Paradis I L, Similo S et al..
Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis
of risk factors and management.
J Thorac Cardiovasc Surg.
1995;
110
4-13
- 63
Valentine V G, Robbins R C, Berry G J et al..
Actuarial survival of heart-lung and bilateral sequential lung transplant recipients
with obliterative bronchiolitis.
J Heart Lung Transplant.
1996;
15
371-383
- 64
van den Berg J WK, Geertsma A, van de Bij W et al..
Bronchiolitis obliterans syndrome after lung transplantation and health-related quality
of life.
Am J Respir Crit Care Med.
2000;
161
1937-1941
- 65
Halloran P F, Homik J, Goes N et al..
The “injury response”: a concept linking nonspecific injury, acute rejection, and
long-term transplant outcomes.
Transplant Proc.
1997;
29
79-81
- 66
Egan J J.
Obliterative bronchiolitis after lung transplantation: a repetitive multiple injury
airway disease.
Am J Respir Crit Care Med.
2004;
170
931-932
- 67
Ross D J, Marchevsky A, Kramer M, Kass R M.
Refractoriness of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis
in pulmonary allografts.
J Heart Lung Transplant.
1997;
16
832-838
- 68
Jaramillo A, Smith M A, Phelan D et al..
Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis
obliterans syndrome and correlates with progressive decline in pulmonary function
after lung transplantation.
Transplantation.
1999;
67
1155-1156
- 69
Palmer S M, Davis R D, Hadjiliadis D et al..
Development of an antibody specific to major histocompatibility antigens detectable
by flow cytometry after lung transplant is associated with bronchiolitis obliterans
syndrome.
Transplantation.
2002;
74
799-804
- 70
Reznik S I, Jaramillo A, Zhang L, Patterson G A, Cooper J D, Mohanakumar T.
Anti-HLA antibody binding to HLA class I molecules induces proliferation of airway
epithelial cells: a potential mechanism for bronchiolitis obliterans syndrome.
J Thorac Cardiovasc Surg.
2000;
119
39-45
- 71
Kroshus T J, Kshettry V R, Savik K, John R, Hertz M I, Bolman III R M.
Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation.
J Thorac Cardiovasc Surg.
1997;
114
195-202
- 72
Girgis R E, Tu I, Berry G J et al..
Risk factors for the development of obliterative bronchiolitis after lung transplantation.
J Heart Lung Transplant.
1996;
15
1200-1208
- 73
Husain A N, Siddiqui M T, Holmes E W et al..
Analysis of risk factors for the development of bronchiolitis obliterans syndrome.
Am J Respir Crit Care Med.
1999;
159
829-833
- 74
Tamm M, Aboyoun C L, Chhajed P N, Rainer S, Malouf M A, Glanville A R.
Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans
syndrome.
Am J Respir Crit Care Med.
2004;
170
1120-1123
- 75
Ruttmann E, Geltner C, Bucher B et al..
Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans
syndrome (BOS) after lung transplantation.
Transplantation.
2006;
81
1415-1420
- 76
Glanville A R, Gencay M, Tamm M et al..
Chlamydia pneumoniae infection after lung transplantation.
J Heart Lung Transplant.
2005;
24
131-136
- 77
Kotsimbos T C, Snell G I, Levvey B et al..
Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome
after lung transplantation.
Transplantation.
2005;
79
269-275
- 78
Neurohr C, Huppmann P, Leuchte H et al..
Human herpesvirus 6 in bronchoalveolar lavage fluid after lung transplantation: a
risk factor for bronchiolitis obliterans syndrome?.
Am J Transplant.
2005;
5
2982-2991
- 79
D'Ovidio F, Singer L G, Hadjiliadis D et al..
Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung
transplant.
Ann Thorac Surg.
2005;
80
1254-1260
- 80
D'Ovidio F, Mura M, Tsang M et al..
Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation.
J Thorac Cardiovasc Surg.
2005;
129
1144-1152
- 81
Cantu III E, Appel III J Z, Hartwig M G et al..
Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal
reflux disease.
Ann Thorac Surg.
2004;
78
1142-1151
- 82
Davis Jr R D, Lau C L, Eubanks S et al..
Improved lung allograft function after fundoplication in patients with gastroesophageal
reflux disease undergoing lung transplantation.
J Thorac Cardiovasc Surg.
2003;
125
533-542
- 83
Hadjiliadis D, Chaparro C, Gutierrez C et al..
Impact of lung transplant operation on bronchiolitis obliterans syndrome in patients
with chronic obstructive pulmonary disease.
Am J Transplant.
2006;
6
183-189
- 84
Hachem R R, Chakinala M M, Yusen R D et al..
The predictive value of bronchiolitis obliterans syndrome stage 0-p.
Am J Respir Crit Care Med.
2004;
169
468-472
- 85
Lama V N, Murray S, Mumford J A et al..
Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant
recipients.
Am J Respir Crit Care Med.
2005;
172
379-383
- 86
Estenne M, Van Muylem A, Knoop C, Antoine M.
Detection of obliterative bronchiolitis by indexes of ventilation distribution.
Am J Respir Crit Care Med.
2000;
162
1047-1051
- 87
Reynaud-Gaubert M, Thomas P, Badier M, Cau P, Giudicelli R, Fuentes P.
Early detection of airway involvement in obliterative bronchiolitis after lung transplantation:
functional and bronchoalveolar lavage cell findings.
Am J Respir Crit Care Med.
2000;
161
1924-1929
- 88
Van Muylem A, Scillia P, Knoop C, Paiva M, Estenne M.
Single-breath test in lateral decubitus reflects function of single lungs grafted
for emphysema.
J Appl Physiol.
2006;
100
834-838
- 89
Gabbay E, Haydn Walters E, Orsida B et al..
In stable lung transplant recipients, exhaled nitric oxide levels positively correlate
with airway neutrophilia and bronchial epithelial iNOS.
Am J Respir Crit Care Med.
1999;
160
2093-2099
- 90
Gabbay E, Walters E H, Orsida B et al..
Post-lung transplant bronchiolitis obliterans syndrome (BOS) is characterized by increased
exhaled nitric oxide levels and epithelial inducible nitric oxide synthase.
Am J Respir Crit Care Med.
2000;
162
2182-2187
- 91
Zheng L, Whitford H M, Orsida B et al..
The dynamics and associations of airway neutrophilia post lung transplantation.
Am J Transplant.
2006;
6
599-608
- 92
Fisher A J, Gabbay E, Small T, Doig S, Dark J H, Corris P A.
Cross-sectional study of exhaled nitric oxide levels following lung transplantation.
Thorax.
1998;
53
454-458
- 93
Verleden G M, Dupont L J, Van Raemdonck D E, Vanhaecke J.
Accuracy of exhaled nitric oxide measurements for the diagnosis of bronchiolitis obliterans
syndrome after lung transplantation.
Transplantation.
2004;
78
730-733
- 94
Brugiere O, Thabut G, Mal H et al..
Exhaled NO may predict the decline in lung function in bronchiolitis obliterans syndrome.
Eur Respir J.
2005;
25
813-819
- 95 Estenne M, Van Muylem A, Knoop C. Comparison of exhaled nitric oxide (eNO) and
helium slope (She) for early detection of graft dysfunction after heart-lung (HLT) and bilateral lung
(BLT) transplantation [abstract]. Proceedings of the American Thoracic Society 2006:
A829
- 96
Barnes P J, Chowdhury B, Kharitonov S A et al..
Pulmonary biomarkers in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
Published ahead of print on March 23, 2006;
174
6-14
- 97
Dupont L J, Dewandeleer Y, Vanaudenaerde B M, Van Raemdonck D E, Verleden G M.
The pH of exhaled breath condensate of patients with allograft rejection after lung
transplantation.
Am J Transplant.
2006;
6
1486-1492
- 98
Allen D J, Fildes J E, Yonan N, Leonard C T.
Changes in induced sputum in the presence of bronchiolitis obliterans syndrome and
correlation with spirometry in single and bilateral lung transplant recipients.
J Heart Lung Transplant.
2005;
24
88-91
- 99
Bankier A A, Muylem A V, Knoop C, Estenne M, Gevenois P A.
BOS in heart-lung transplant recipients: diagnosis with expiratory CT.
Radiology.
2001;
218
533-539
- 100
Gast K K, Zaporozhan J, Ley S et al..
3He-MRI in follow-up of lung transplant recipients.
Eur Radiol.
2004;
14
78-85
- 101 Verleden G M, Dupont L J.
Obliterative bronchiolitis. In: Lynch III JP, Ross DJ Lung and Heart-Lung Transplantation New York; Taylor and
Francis Group 2006: 723-751
- 102
Johnson B A, Iacono A T, Zeevi A, McCurry K R, Duncan S R.
Statin use is associated with improved function and survival of lung allografts.
Am J Respir Crit Care Med.
2003;
167
1271-1278
- 103
Gerhardt S G, McDyer J F, Girgis R E, Conte J V, Yang S C, Orens J B.
Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of
a pilot study.
Am J Respir Crit Care Med.
2003;
168
121-125
- 104
Verleden G M, Dupont L J.
Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung
transplantation.
Transplantation.
2004;
77
1465-1467
- 105
Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer M R.
Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung
transplant recipients.
J Heart Lung Transplant.
2005;
24
1440-1443
- 106
Yates B, Murphy D M, Forrest I A et al..
Azithromycin reverses airflow obstruction in established bronchiolitis obliterans
syndrome.
Am J Respir Crit Care Med.
2005;
172
772-775
- 107
Verleden G M, Vanaudenaerde B M, Dupont L J, Van Raemdonck D E.
Azithromycin reduces airway neutrophilia and IL-8 in patients with bronchiolitis obliterans
syndrome.
Am J Respir Crit Care Med.
Published ahead of print on June 1, 2006;
174
566-570
- 108
Fisher A J, Rutherford R M, Bozzino J, Parry G, Dark J H, Corris P A.
The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis
obliterans syndrome after lung transplantation.
Am J Transplant.
2005;
5
537-543
- 109
Novick R J, Stitt L W, Al-Kattan K et al..
Pulmonary retransplantation: predictors of graft function and survival in 230 patients.
Pulmonary Retransplant Registry.
Ann Thorac Surg.
1998;
65
227-234
Marc EstenneM.D.
Chest Service, Erasme University Hospital
808, Route de Lennik, B-1070 Brussels, Belgium
Email: mestenne@ulb.ac.be